A PHASE Ia/Ib, OPEN LABEL, MULTICENTER, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7502175 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS - GO43860 Study

Genentech Inc. c/o F. Hoffmann-La Roche Ltd0 个研究点目标入组 62 人开始时间: 待定最近更新: 2024年4月9日

研究概览

暂无简介。

•- Age >= 18 years
•- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
•- Life expectancy >= 12 weeks
•- Adequate hematologic and end-organ function
•- Histologically confirmed locally advanced, recurrent, or metastatic incurable
•solid tumor malignancy
•- Availability of representative tumor specimens
•- Measurable disease per Response Evaluation Criteria in Solid Tumors Version
•1.1 (RECIST v1.1)
•- For women of childbearing potential: agreement to remain abstinent (refrain
•from heterosexual intercourse) or use contraception, and agreement to refrain
•from donating eggs
•- For men: agreement to remain abstinent (refrain from heterosexual
•intercourse) or use contraception, and agreement to refrain from donating sperm

•- Pregnant or breastfeeding, or intending to become pregnant during the study
•or within 5 months after the final dose of study treatment
•- Symptomatic, untreated, or actively progressing central nervous system (CNS)
•- History of leptomeningeal disease
•- Significant cardiovascular disease within 3 months prior to initiation of
•study treatment
•- History of malignancy other than disease under study within 3 years prior to
•- Any immune-mediated adverse events related to prior cancer immunotherapy that
•have not resolved completely to baseline
•- Active or history of autoimmune disease or immune deficiency
•- Active tuberculosis, hepatitis B or acute or chronic active EBV infection
•- Positive test for human immunodeficiency virus (HIV) infection
•- Positive hepatitis C virus (HCV) antibody test
•- Known infection with severe acute respiratory syndrome coronavirus 2
•(SARS-CoV-2)
•- Major surgical procedure or significant traumatic injury within 28 days prior
•to first study drug infusion
•- Prior allogeneic stem cell or organ transplantation

发起方

Genentech Inc. c/o F. Hoffmann-La Roche Ltd